Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Status:
Recruiting
Trial end date:
2025-02-14
Target enrollment:
Participant gender:
Summary
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase
2, 3-arm study in adult participants with moderate to severe AD who are inadequately
controlled with topical therapies or for whom such topical therapies are inadvisable and who
are candidates for systemic therapy.
Participants will be randomized to receive SAR444656 dose 1, SAR444656 dose 2 or matching
placebo.
Participants who meet inclusion/exclusion criteria will be stratified for randomization by
severity of AD (moderate [baseline EASI score <22] versus severe [baseline EASI score ≥22]).
The total duration of study is approximately 24 weeks, including 1 to 4 weeks for screening,
16 weeks for double-blind study treatment and 4 weeks for follow-up.